Xuena Wang

Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia

David J. Kuter, Mathias Rummel, Ralph V. Boccia et al. · New England Journal of Medicine · 2010 · 423 citations · Full text

Medicine, Hematology, Pharmacology +9

Detection of cancer-specific markers amid massive mass spectral data

Wei Zhu, Xuena Wang, Yeming Ma et al. · Proceedings of the National Academy of Sciences · 2003 · 183 citations · Full text

Life Sciences, Biochemistry, Oncology +17

Long‐term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials

Francesco Rodeghiero, Roberto Stasi, Aristoteles Giagounidis et al. · European Journal Of Haematology · 2013 · 113 citations

Medicine, Hematology, Pharmacology +15

Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim

Douglas B. Cines, Terry Gernsheimer, Jeffrey S. Wasser et al. · International Journal of Hematology · 2015 · 97 citations

Medicine, Hematology, Pharmacology +8

Health‐related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care

David J. Kuter, Susan D. Mathias, Mathias Rummel et al. · American Journal of Hematology · 2012 · 78 citations

Life Sciences, Hematology, Pharmacotherapy +13